To break it down: The first part of the name, HER2, stands for “human epidermal growth factor receptor 2.” This refers to a protein found on the surface of breast cells that helps direct how quickly ...
Dr Avan Armaghani discusses earlier use of ADCs, artificial intelligence for recurrence prediction, and new endocrine therapy ...
Most types of breast cancer produce similar symptoms and are discovered the same way—finding a strange new lump during a self-exam, or a healthcare provider spotting something suspicious during a ...
Jenna Fischer, who starred in "The Office," said Tuesday that she underwent surgery and treatment for breast cancer earlier this year and is now "cancer free." Fischer, 50, wrote in an Instagram post ...
Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer PURPOSE: Few studies have examined the ...
Nat Clin Pract Oncol. 2008;5(9):531-542. The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With ...
Breast cancer types include IDC, ILC, HR+, HER2-positive, and triple-negative, each with distinct characteristics and treatment implications. Staging from 0 to IV helps determine treatment plans and ...
Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the CCTG BR.34 Trial Human epidermal ...
Hosted on MSN
A Promising New Option For PIK3CA-Mutated Breast Cancer: What New Data On Inavolisib Could Mean for You
Some breast cancers “feed” on the hormone estrogen. These are usually treated with medicines that either block estrogen’s signal (fulvestrant) or slow the cancer’s growth cycle (palbociclib). In about ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted ...
The lidERA Breast Cancer study is a phase 3, randomized, open-label trial testing whether the adjuvant therapy giredestrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results